Drug Price Trends for NDC 17772-0102

Average Pharmacy Cost for 17772-0102

Drug Name	NDC	Price/Unit ($)	Unit	Date
TROKENDI XR 50 MG CAPSULE	17772-0102-30	16.27123	EACH	2026-03-18
TROKENDI XR 50 MG CAPSULE	17772-0102-30	16.20150	EACH	2026-02-18
TROKENDI XR 50 MG CAPSULE	17772-0102-30	16.20157	EACH	2025-10-01
TROKENDI XR 50 MG CAPSULE	17772-0102-30	15.28450	EACH	2025-09-17
TROKENDI XR 50 MG CAPSULE	17772-0102-30	15.27949	EACH	2025-08-20

Best Wholesale Price for NDC 17772-0102

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
TROKENDI XR 50MG CAP	Supernus Pharmaceuticals, Inc.	17772-0102-01	100	926.64	9.26640	2022-09-15 - 2027-09-14	Big4
TROKENDI XR 50MG CAP	Supernus Pharmaceuticals, Inc.	17772-0102-01	100	1172.54	11.72540	2022-09-15 - 2027-09-14	FSS
TROKENDI XR 50MG CAP	Supernus Pharmaceuticals, Inc.	17772-0102-01	100	1096.03	10.96030	2023-01-01 - 2027-09-14	Big4
TROKENDI XR 50MG CAP	Supernus Pharmaceuticals, Inc.	17772-0102-01	100	1172.54	11.72540	2023-01-01 - 2027-09-14	FSS
TROKENDI XR 50MG CAP	Supernus Pharmaceuticals, Inc.	17772-0102-01	100	1046.36	10.46360	2023-03-01 - 2027-09-14	Big4

Market Analysis and Price Projections for NDC 17772-0102

Last updated: February 24, 2026

What is NDC 17772-0102?

NDC 17772-0102 is a prescription drug marketed by Gilead Sciences. It is a fixed-dose combination product containing bictegravir, emtricitabine, and tenofovir alafenamide. Primarily, the drug is used for the treatment of HIV-1 infection.

Market Size and Demand Dynamics

Current Market Landscape

• Global HIV drug market estimated at $23 billion in 2022.
• US market dominated by antiretroviral therapies (ARVs), with Gilead holding approximately 85% share.
• NDC 17772-0102, marketed as Biktarvy, accounts for nearly 30% of the US HIV therapy market segment.

Prescribing Trends

• Growing HIV prevalence: 1.2 million Americans living with HIV as of 2022.
• Treatment adherence targets: 80-85% of diagnosed patients receive consistent therapy.
• NDC 17772-0102's advantages include once-daily dosing, high efficacy, and a favorable side effect profile.

Competitive Landscape

Drug Name	Market Share (2022)	Key Features	Price Point (per month)
Biktarvy	30%	Once-daily, high efficacy, tolerability	$3,000 - $3,500
Truvada	20%	Widely used, lower price, filled with tenofovir disoproxil	$2,200 - $2,700
Descovy	15%	Better renal/bone safety profile	$2,500 - $3,000
Other ARVs	35%	Variety, including generics	$1,000 - $2,500

Market Drivers and Constraints

• Increasing HIV diagnosis rates.
• Advancements reducing pill burden and side effects.
• Patent protections until 2030; biosimilar competition remains limited.
• Price sensitivity among payers limits maximum permissible pricing.

Price Projections

Short-term (Next 1-2 Years)

• Stable pricing around $3,000 per month due to patent exclusivity.
• No immediate generic competition anticipated until patent expiration or legal challenges.
• Minor price reductions possible as payers negotiate rebates and discounts.

Medium-term (3-5 Years)

• Potential for slight price erosion (~5-10%) driven by contract negotiations and market saturation.
• Entry of biosimilars or generics post-2030 could drive prices down by 20-30%.
• Price ceilings could be influenced by national patent law reforms or policy interventions.

Long-term (Beyond 5 Years)

• Substantial price declines expected: 30-50% once biosimilar/generic options gain approval and market share.
• Innovation in drug formulations (such as long-acting injectables) might shift demand away from oral fixed-dose combos, affecting original prices.

Regulatory and Policy Factors Impacting Price Trends

• Patent protections until 2030 restrict generic entry.
• Medicare and Medicaid negotiations can influence pricing strategies.
• CDC and FDA guidelines favor increasing use of cost-effective regimens.
• Law reforms aiming at reducing drug prices could reshape the market landscape.

Strategic Considerations for Stakeholders

• Pharmaceutical companies should plan for patent sunset strategies.
• Payers and insurers should leverage negotiations and formulary management to control costs.
• Investors should monitor pipeline developments and potential biosimilar entries.

Summary of Key Data Points

Parameter	Current Estimate	Notes
Market Size (global, 2022)	$23 billion	HIV sector overall
US HIV treatment market share	$6-7 billion	Gilead holds ~85%
NDC 17772-0102’s US market share	30% of HIV therapy segment	Biktarvy sales dominance
Monthly price	$3,000 - $3,500	Stable, patent-protected
Patent expiration	2030	Patent protections sustain current pricing

Conclusions

• Short-term pricing remains stable due to patent protections and monopole status.
• Medium-term expects modest price decline as contracts become more competitive.
• Long-term forecasts significant price drops following patent expiry and biosimilar entry.

Key Takeaways

• NDC 17772-0102 (Biktarvy) dominates US HIV treatment with a high market share.
• Prices are expected to stay around current levels through 2030, barring policy changes.
• Post-2030, biosimilars and generics could reduce prices by up to 50%.
• The HIV treatment landscape shifts toward long-acting formulations, potentially impacting the drug’s market share.
• Payers and stakeholders should build strategies considering patent timelines and evolving treatment protocols.

FAQs

1. When is patent expiration expected for NDC 17772-0102?

   • Patent protections extend until 2030.

2. How can biosimilars influence the market after patent expiry?

   • Biosimilars can provide lower-cost alternatives, reducing prices by 20-50%.

3. What are the main competitors of Biktarvy?

   • Truvada and Descovy are key competitors, with alternative formulations and safety profiles.

4. Will price reductions occur before patent expiration?

   • Minor reductions may stem from negotiations, rebates, and formulary discounts.

5. How is the market adapting to long-acting HIV treatments?

   • Long-acting injectables are gaining approval, potentially decreasing reliance on daily oral therapies like Biktarvy.

---

References

[1] IQVIA. (2022). HIV drugs market report. IQVIA Insights.

[2] Gilead Sciences. (2022). Biktarvy prescribing information. Gilead.

[3] CDC. (2022). HIV Surveillance Report. Centers for Disease Control and Prevention.

[4] FDA. (2023). Long-acting injectable HIV treatments approval. U.S. Food and Drug Administration.

[5] S&P Global Market Intelligence. (2022). Pharma pricing trends.